Gamma secretase modulators

1. A compound of the formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

R 6 and R 7 are each independently selected from the group consisting of: H, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , alkyl-, alkenyl- and alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl- and heterocyclyalkyl-, benzofusedcycloalkyl, fused benzoheterocycloalkyl, fused heteroarylcycloalkyl, fused heteroarylheterocycloalkyl; and wherein each of said R 6 and R 7 alkyl-, alkenyl-, alkynyl-, aryl-, arylalkyl-, alkylaryl-, cycloalkyl-, cycloalkylalkyl-, heteroaryl-, heteroarylalkyl-, heterocyclyl-, heterocyclyalkyl-, benzofusedcycloalkyl, fused benzoheterocycloalkyl, fused heteroarylcycloalkyl, and fused heteroarylheterocycloalkyl group is optionally substituted with 1-5 independently selected R 21 substituents;

the R 9 —R 10 moiety is selected from the group consisting of

each R 15A is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylcycloalkyl, arylheterocyclyl, (R 18 ) 1-5 -alkyl, (R 18 ) 1-5 -cycloalkyl, (R 18 ) 1-5 -cycloalkylalkyl, (R 18 ) 1-5 -heterocyclyl, (R 18 ) 1-5 -heterocyclylalkyl, (R 18 ) 1-5 -aryl, (R 18 ) 1-5 -arylalkyl, (R 18 ) 1-5 -heteroaryl and (R 18 ) 1-5 -heteroarylalkyl; and wherein each R 18 in each group can be on any substitutable atom;

each R 16A is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylcycloalkyl, arylheterocyclyl, (R 18 ) 1-5 -alkyl, (R 18 ) 1-5 -cycloalkyl, (R 18 ) 1-5 -cycloalkylalkyl, (R 18 ) 1-5 -heterocyclyl, (R 18 ) 1-5 -heterocyclylalkyl, (R 18 ) 1-5 -aryl, (R 18 ) 1-5 -arylalkyl, (R 18 ) 1-5 -heteroaryl and (R 18 ) 1-5 -heteroarylalkyl; and wherein each R 18 in each group can be on any substitutable atom;

R 15 , R 16 and R 17 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylcycloalkyl, arylheterocyclyl, (R 18 ) 1-5 -alkyl, (R 18 ) 1-5 -cycloalkyl, (R 18 ) 1-5 -cycloalkylalkyl, (R 18 ) 1-5 -heterocyclyl, (R 18 ) 1-5 -heterocyclylalkyl, (R 18 ) 1-5 -aryl, (R 18 ) 1-5 -arylalkyl, (R 18 ) 1-5 -heteroaryl and

(R 18 ) 1-5 -heteroarylalkyl; and wherein each R 18 in each group can be on any substitutable atom;

each R 18 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, —NO 2 , halo, heteroaryl, HO-alkyoxyalkyl, —CF 3 , —CN, alkyl-CN, —C(O)R 19 , —C(O)OH, —C(O)OR 19 , —C(O)NHR 20 , —C(O)NH 2 , —C(O)NH 2 —C(O)N(alkyl) 2 , —C(O)N(alkyl)(aryl), —C(O)N(alkyl)(heteroaryl), —SR 19 , —S(O) 2 R 20 , —S(O)NH 2 , —S(O)NH(alkyl), —S(O)N(alkyl)(alkyl), —S(O)NH(aryl), —S(O) 2 NH 2 , —S(O) 2 NHR 19 , —S(O) 2 NH(heterocyclyl), —S(O) 2 N(alkyl) 2 , —S(O) 2 N(alkyl)(aryl), —OCF 3 , —OH, —OR 20 , —O-heterocyclyl, —O-cycloalkylalkyl, —O-heterocyclylalkyl, —NH 2 , —NHR 20 , —N(alkyl) 2 , —N(arylalkyl) 2 , —N(arylalkyl)-(heteroarylalkyl), —NHC(O)R 20 , —NHC(O)NH 2 , —NHC(O)NH(alkyl), —NHC(O)N(alkyl)(alkyl), —N(alkyl)C(O)NH(alkyl), —N(alkyl)C(O)N(alkyl)(alkyl), —NHS(O) 2 R 20 , —NHS(O) 2 NH(alkyl), —NHS(O) 2 N(alkyl)(alkyl), —N(alkyl)S(O) 2 NH(alkyl) and —N(alkyl)S(O) 2 N(alkyl)(alkyl);

or, two R 18 moieties on adjacent carbons can be taken together with the atoms to which they are bound to form:

R 19 is selected from the group consisting of: alkyl, cycloalkyl, aryl, arylalkyl and heteroarylalkyl;

R 20 is selected from the group consisting of: alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl, heteroaryl and heteroarylalkyl;

each R 21 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, halo, —CN, —OR 15 , —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —SF 5 , —OSF 5 , —Si(R 15A ) 3 wherein each R 15A is independently selected, —SR 15 , —S(O)N(R 15 )(R 16 ), —CH(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —N(R 15 )(R 16 ), -alkyl-N(R 15 )(R 16 ), —N(R 15 )C(O)R 16 , —CH 2 —N(R 15 )C(O)R 16 , —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —CH 2 —R 15 ; —CH 2 N(R 15 )(R 16 ), —N(R 15 )S(O)R 16A , —N(R 15 )S(O) 2 R 16A , —CH 2 —N(R 15 )S(O) 2 R 16A , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —CH 2 —N(R 15 )C(O)OR 16 , —S(O)R 15A , —N 3 , —NO 2 and —S(O) 2 R 15A ; and, optionally, each of said alkyl, cycloalkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkenyl and alkynyl R 21 groups are substituted with 1 to 5 independently selected R 22 groups; and

each R 22 is independently selected from the group consisting of: alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, halo, —CF 3 , —CN, —OR 15 , —C(O)R 15 , —C(O)OR 15 , -alkyl-C(O)OR 15 , C(O)N(R 15 )(R 16 ), —SF 5 , —OSF 5 , —Si(R 15A ) 3 wherein each R 15A is independently selected, —SR 15 , —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —N(R 15 )(R 16 ), -alkyl-N(R 15 )(R 16 ), —N(R 15 )C(O)R 16 , —CH 2 —N(R 15 )C(O)R 16 , —N(R 15 )S(O)R 16A , —N(R 15 )S(O) 2 R 16A , —CH 2 —N(R 15 )S(O) 2 R 16A , —N(R 15 )S(O) 2 N(R 16 )(R 17 ), —N(R 15 )S(O)N(R 16 )(R 17 ), —N(R 15 )C(O)N(R 16 )(R 17 ), —CH 2 —N(R 15 )C(O)N(R 16 )(R 17 ), —N(R 15 )C(O)OR 16 , —CH 2 —N(R 15 )C(O)OR 16 , —N 3 , ═NOR 15 , —NO 2 , —S(O)R 15A and —S(O) 2 R 15A .

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 6 is alkyl, and R 7 is a substituted aryl group.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 7 is:

phenyl, or

phenyl substituted with one or more independently selected R 21 groups, or

phenyl substituted with 1 to 3 independently selected R 21 groups, or

phenyl substituted with 1 to 3 R 21 groups, wherein each R 21 group is the same or different halo, or

phenyl substituted with 1 to 3 F, or

phenyl substituted with one —CN group, or

phenyl substituted with one or two —CF 3 groups, or

phenyl substituted with R 21 groups, wherein the R 21 group is selected from the group consisting of: —SF 5 , —OSF 5 and —Si(R 15A ) 3 , and wherein each R 15A is independently selected, or

phenyl substituted with R 21 groups wherein the R 21 group is selected from the group consisting of: —SF 5 , —OSF 5 and —Si(R 15A ) 3 , and wherein each R 15A is the same or different alkyl group, or

or

phenyl substituted with R 21 groups wherein the R 21 group is selected from the group consisting of: —SF 5 , —OSF 5 and —Si(CH 3 ) 3 .

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from the group consisting of:

5. The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein R 6 is alkyl.

6. The compound of claim 1 selected from the group consisting of: compounds

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. A method for treating Alzheimer's disease, the method comprising administering an effective amount of one or more compounds of claim 1 or a pharmaceutically acceptable salt thereof to a patient in need of treatment.

9. A method for treating Alzheimer's disease, the method comprising administering an effective amount of one or more compounds of claim 6 or a pharmaceutically acceptable salt thereof to a patient in need of treatment.

10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the R 9 —R 10 moiety is